1-15 of 15
Li Fei
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Is the 2 nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Sen Yang, Xiaoshuai Zhang, Yanli Zhang, Xin Du, Jianyu Weng, Huanling Zhu, Ling Pan, Yun-fan Yang, Li Meng, Zhenfang Liu, Xiaoli Liu, Na Xu, Chunyan Chen, Xiaodong WANG, Rong Liang, Jian Huang, Guohui Li, Chunshui Liu, Hai Lin, Jianda Hu, Li Fei, Bingcheng Liu, Weiming Li, Zhuogang Liu, Wei Yang, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 815–817.
https://doi.org/10.1182/blood-2022-166855
Published: 2022
Journal Articles

Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yunfan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9620–9623.
https://doi.org/10.1182/blood-2022-166431
Published: 2022
Journal Articles

Hemophagocytic Lymphohistiocytosis Patients Need Intensive Care Can be Successfully Rescued By Timely Using Etoposide-Based HLH Regimens

Lv Kebing, Cheng Xiaoye, Zhou Yulan, Shen Huimin, Li Fei
Journal: Blood
Blood (2022) 140 (Supplement 1): 11322.
https://doi.org/10.1182/blood-2022-156086
Published: 2022
Journal Articles

A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yun-fan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9637–9639.
https://doi.org/10.1182/blood-2022-168703
Published: 2022
Journal Articles

Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Jun Ma, Yuqin Song, Yan Xie, Hui-Lai Zhang, Yuerong Shuang, Zhigang Peng, Li Fei, Yunhong Huang, Weili Zhao, Wenrong Huang, Yali Pan, Mingying Liu, Feiwu Ran, Hui Feng, Sheng Yao, Patricia Keegan, Jianjun Zou, Jun Zhu
Journal: Blood
Blood (2022) 140 (Supplement 1): 3716–3717.
https://doi.org/10.1182/blood-2022-157497
Published: 2022
Journal Articles

Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor

Xiaoshuai Zhang, Bingcheng Liu, Jian Huang, Gongli Zhang, Xiaoli Liu, Na Xu, Weiming Li, Xin Du, Jianyu Weng, Hai Lin, Rong Liang, Chunyan Chen, Huanling Zhu, Ling Pan, Yun-fan Yang, Xiaodong WANG, Guohui Li, Zhuogang Liu, Zhenfang Liu, Jianda Hu, Chunshui Liu, Li Fei, Wei Yang, Li Meng, Robert Peter Gale, Xiao Jun Huang, Qian Jiang
Journal: Blood
Blood (2022) 140 (Supplement 1): 3891–3894.
https://doi.org/10.1182/blood-2022-168812
Published: 2022
Journal Articles

Results from a Phase 2 Study of a Novel Janus Kinase Inhibitor in Treatment of Patients with Myelofibrosis

Yi Zhang, Hu Zhou, Zhongxing Jiang, DengShu Wu, Junling Zhuang, Wei Li, Qian Jiang, XiuLi Wang, Jinwen Huang, Huan-Ling Zhu, RuiJuan Zhang, Xin Du, Li Fei, Ruixiang Xiang, Feng Zhang, Jianda Hu, Yan Li, Yu Hu, Jing Liu, ChengHao Jin, Kai Sun, Ze-Ping Zhou, Jie Jin
Journal: Blood
Blood (2021) 138 (Supplement 1): 387.
https://doi.org/10.1182/blood-2021-145664
Published: 2021
Journal Articles

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

Lugui Qiu, Weijun Fu, Zhongjun Xia, Zhengzheng Fu, Wenming Chen, Chunkang Chang, Baijun Fang, Gang An, Yongqiang Wei, Zhen Cai, Sujun Gao, Jianyu Weng, Lijuan Chen, Hongmei Jing, Li Fei, Zhuogang Liu, Xiequn Chen, Jing Liu, Yang Yu, Aihua Wang, Yijun Yang, Zhinuan Yu, Kevin Lynch
Journal: Blood
Blood (2021) 138 (Supplement 1): 4770.
https://doi.org/10.1182/blood-2021-145282
Published: 2021
Journal Articles

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

Weijun Fu, Lugui Qiu, Zhongjun Xia, Zhengzheng Fu, Wenming Chen, Chunkang Chang, Baijun Fang, Gang An, Yongqiang Wei, Zhen Cai, Sujun Gao, Jianyu Weng, Lijuan Chen, Hongmei Jing, Li Fei, Zhuogang Liu, Xiequn Chen, Jing Liu, Yang Yu, Aihua Wang, Zhinuan Yu, Yijun Yang, Kevin Lynch
Journal: Blood
Blood (2021) 138 (Supplement 1): 4778.
https://doi.org/10.1182/blood-2021-146784
Published: 2021
Journal Articles

Rituximab Biosimilar Combined with Pegylated Interferon α-2b in Patients with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Preliminary Results from a Multicenter, Single-Arm, Phase II Study

Gao Yan, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Li Fei, Xiaoxiao Wang, Bing Bai, Yuhua Huang, Haixia He, Liqin Ping, Yanxia He, Cheng Huang, Jibin Li, Jiaying Mao, Huiqiang Huang
Journal: Blood
Blood (2021) 138 (Supplement 1): 1359.
https://doi.org/10.1182/blood-2021-152018
Published: 2021
Journal Articles

Changes of Peripheral Blood Lymphocyte Subsets and Cytokines in Patients with Multiple Myeloma and Their Clinical Significance

Li Fei
Journal: Blood
Blood (2020) 136 (Supplement 1): 38.
https://doi.org/10.1182/blood-2020-142759
Published: 2020
Journal Articles

A Multicenter Real-Life Study of Polatuzumab Vedotin Combined with Immunochemotherapy in Patients with R/R DLBCL: Preliminary Data on Efficacy and Safety in Chinese Cohort

Jianqiu Wu, Yanyan Liu, Li Fei, Zhi-Jun Wuxiao, Fancong Kong, Zhihua Yao, Weilun Zhou, Jifeng Feng
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-142553
Published: 2020
Journal Articles

Waldenström's Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals

Xin-xin Cao, MD, Shuhua Yi, MD, Zhongxing Jiang, MD, Jingsong He, MD, Wei Yang, Juan Du, Jr., MD, Chunyan Sun, MD PhD, Yu Wu, MD, Chen Wenming, MD, Xiao-jun Liu, Bingzong Li, MDPhD, Chunrui Li, MDPhD, Wei Sang, Qin-hua Liu, Xiaoxia Chu, Li Fei, Ou Bai, Min Mao, Rong Fu, PhD, Wei WANG, MD, Lihong Liu, MD, Luqun Wang, MDPhD, Yujun Dong, MD, Jun Luo, DO, Zhenling Li, Yongqiang Wei, Qi-ke Zhang, Jing Liu, Kaiyang Ding, Liang Zou, Bi-yun Chen, Luoming Hua, PhD, Hongmei Jing, Juan He, PhD, Liang Wang, Lugui Qiu, MD, Jian Li, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-134785
Published: 2020
Journal Articles

Heterogeneous BCR-ABL Signal Patterns Identified By Fluorescence in Situ Hybridization Can Predict Leukemic Clonal Evolution and Poor Prognosis in BCR-ABL-Positive Leukemia

Zhang Zhanglin, Wan Lagen, Jiang Mei, Liu Shuyuan, Guo Yang, Li Fei, PhD MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1441.
https://doi.org/10.1182/blood.V130.Suppl_1.1441.1441
Published: 2017
Journal Articles

Serum Mir-4254, Mir-19a and Mir-33b Are Potential Markers For Diagnosis and Prognostic Evaluation In Multiple Myeloma

Mu Hao, PhD., Meirong Zang, Qin Yu, Li Fei, Wenjuan Yang, Xiaoyan Feng, Fang Qi, Gang An, Changhong Li, Yan Xu, MD., Fenghuang Zhan, MD&PhD, Lugui Qiu, MD
Journal: Blood
Blood (2013) 122 (21): 3222.
https://doi.org/10.1182/blood.V122.21.3222.3222
Published: 2013